World journal of clinical oncology最新文献

{"title":"Potential regulatory mechanism and clinical significance of synaptotagmin binding cytoplasmic RNA interacting protein in colorectal cancer.","authors":"Hui Li, He-Qing Huang, Zhi-Guang Huang, Rong-Quan He, Ye-Ying Fang, Rui Song, Jia-Yuan Luo, Da-Tong Zeng, Kai Qin, Dan-Ming Wei, Gang Chen","doi":"10.5306/wjco.v15.i11.1412","DOIUrl":"https://doi.org/10.5306/wjco.v15.i11.1412","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) causes many deaths worldwide. Synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP) is an RNA-binding protein that plays an important role in multiple cancers by epigenetically targeting some genes. Our study will examine the expression, potential effect, biological function and clinical value of SYNCRIP in CRC.</p><p><strong>Aim: </strong>To examine the expression, potential effect, biological function and clinical value of SYNCRIP in CRC.</p><p><strong>Methods: </strong>The expression of SYNCRIP was examined by immunohistochemistry arrays and high-throughput data. The effect of SYNCRIP gene in CRC cell growth was evaluated by CRISPR-Cas9 technology. The target genes of SYNCRIP were calculated using various algorithms, and the molecular mechanism of SYNCRIP in CRC was explored by mutation analysis and pathway analysis. The clinical value of SYNCRIP in prognosis and radiotherapy was revealed <i>via</i> evidence-based medicine methods.</p><p><strong>Results: </strong>The protein and mRNA levels of SYNCRIP were both highly expressed in CRC samples compared to nontumorous tissue based on 330 immunohistochemistry arrays and 3640 CRC samples. Cells grew more slowly in eleven CRC cell lines after knocking out the SYNCRIP gene. SYNCRIP could epigenetically target genes to promote the occurrence and development of CRC by boosting the cell cycle and affecting the tumor microenvironment. In addition, CRC patients with high SYNCRIP expression are more sensitive to radiotherapy.</p><p><strong>Conclusion: </strong>SYNCRIP is upregulated in CRC, and highly expressed SYNCRIP can accelerate CRC cell division by exerting its epigenetic regulatory effects. In addition, SYNCRIP is expected to become a potential biomarker to predict the effect of radiotherapy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1412-1427"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole exome sequencing identifies risk variants associated with intracranial epidermoid cyst deterioration: A case report.","authors":"Zhao-Na Song, Yan Cheng, Dan-Dan Wang, Ming-Jun Li, Xiang-Rong Zhao, Fa-Wang Li, Zhen Liu, Xiao-Ru Zhu, Xiao-Dong Jia, Yu-Fang Wang, Feng-Fan Liang","doi":"10.5306/wjco.v15.i11.1428","DOIUrl":"https://doi.org/10.5306/wjco.v15.i11.1428","url":null,"abstract":"<p><strong>Background: </strong>Intracranial epidermoid cyst (IEC) transformation to malignant squamous cell carcinoma (SCC) is extremely rare, and its etiology is yet unknown. Currently, SCC is treated by performing surgery, followed by a combination of radiotherapy and chemotherapy. It is crucial to identify efficient and trustworthy therapeutic targets for SCC to improve its diagnosis, prognosis, and treatment.</p><p><strong>Case summary: </strong>In this study, we report the case of a 47-year-old female patient with SCC, which progressed from IEC in the left internal capsule region. The patient was sought treatment at our hospital for severe diplopic vision, accompanied with speech disorder and memory loss. Based on the clinical and postoperative pathology, this patient was finally diagnosed with SCC. To identify disease-causing variants, whole exome sequencing (WES) was performed on the proband. WES revealed two pathogenic missense mutations on Gap junction protein beta 2 (GJB2) (c.257C>T) and Toll-like receptor 2 (TLR2) (c.1039A>G), respectively.</p><p><strong>Conclusion: </strong>This study provided the first clinical evidence for demonstrating the role of GJB2 and TLR2 in IEC development and treatment. We further confirmed WES as a robust and reliable technique for underlying rare and complex disease-related genetic factor identification.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1428-1434"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Well water contaminants and colorectal cancer in North Dakota.","authors":"Amber D Lyon-Colbert, Marc D Basson, Marilyn G Klug, Gary G Schwartz","doi":"10.5306/wjco.v15.i11.1454","DOIUrl":"https://doi.org/10.5306/wjco.v15.i11.1454","url":null,"abstract":"<p><p>This study aims to identify common contaminants in well water linked to an increase in colorectal cancer (CRC) incidence rates in North Dakota (ND) counties. County-specific incidence rates for CRC were obtained from the ND Statewide Cancer Registry. Corresponding demographic, agricultural, and geophysical data were obtained from population-based sources. Associations between well water contaminants and CRC incidence were examined for 16 counties in ND with complete well water profiles between 1997-2019. Data were analyzed by multiple linear regression. Iron in well water exhibited a significant positive association with CRC incidence (4.75, <i>P</i> = 0.001), and barium exhibited a small, but significant negative association (-0.06907, <i>P</i> = 0.01). Residents in counties in ND with prevalent well water usage contaminated with iron may be at higher risk for CRC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1454-1458"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of fat-poor renal angiomyolipoma with ectopic blood supply by fluorescent laparoscopy: A case report and review of literature.","authors":"Jian-Er Tang, Rong-Jiang Wang, Zhi-Hai Fang, Ping-Ya Zhu, Jian-Xiang Yao, Hua Yang","doi":"10.5306/wjco.v15.i11.1435","DOIUrl":"https://doi.org/10.5306/wjco.v15.i11.1435","url":null,"abstract":"<p><strong>Background: </strong>Renal angiomyolipoma and renal cell carcinoma are the most common benign and malignant tumors of the kidney respectively, and the preoperative differential diagnosis is crucial due to the wide difference in treatment methods. Fat-poor renal angiomyolipoma is a relatively rare type of in renal angiomyolipoma. Its fat imaging features are not obvious, and it is easily misdiagnosed as renal cell carcinoma.</p><p><strong>Case summary: </strong>We report the case of a 41-year-old man who complained of osphyalgia. Subsequent abdominal computed tomography scans revealed that a heterogeneous mass was seen in the lower pole of the right kidney, with the size of about 53 mm × 47 mm. And showed two right renal arteries, with the mass supplied by an ectopic vessel from the abdominal aorta. Fluorescent laparoscopic blockade of the right renal heterotopic artery and partial nephrectomy was performed. Based on histological and immunohistochemical findings, the tumor was diagnosed as fat-poor renal angiomyolipoma.</p><p><strong>Conclusion: </strong>The use of fluorescent laparoscopy can effectively help intraoperative management, and the fluorescence pattern provided by intravenous indocyanine green can help suggest the final diagnosis, effectively guide the surgical decision-making, and avoid preoperative imaging diagnosis leading to nephrectomy for benign renal tumors, through fluorescent navigation of tumor supply vessel precise block, minimize the loss of renal function.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1435-1443"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radical radiotherapy without surgical tumor resection for rectal cancer.","authors":"Takashi Ono, Masashi Koto","doi":"10.5306/wjco.v15.i11.1390","DOIUrl":"https://doi.org/10.5306/wjco.v15.i11.1390","url":null,"abstract":"<p><p>In this editorial, I would like to comment on the article, recently published in the <i>World Journal of Clinical Oncology</i>. The article focuses on non-surgical treatments for locally recurrent rectal cancer, including the watch-and-wait (WW) strategy after total neoadjuvant therapy (TNT) and particle beam therapy. As treatment options for rectal cancer continue to evolve, the high complete response rate achieved with TNT has led to the development of a new non-surgical approach: WW. Chemoradiotherapy followed by consolidation chemotherapy, in particular, has a low rate of tumor growth and is a treatment aimed at achieving a cure without surgery. However, the risk of recurrence within two years is significant, necessitating careful follow-up. Establishing standardized follow-up methods that can be implemented by many physicians is essential. Carbon ion radiotherapy has demonstrated high local control with a low incidence of severe late toxicities, even after previous pelvic radiotherapy. While these new non-surgical curative treatments for rectal cancer require further investigation, future advancements in this field are anticipated.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1390-1393"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic treatment of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease.","authors":"Karolina Rzeniewicz, Rohini Sharma","doi":"10.5306/wjco.v15.i11.1394","DOIUrl":"https://doi.org/10.5306/wjco.v15.i11.1394","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally, with 15% of cases arising on a background of non-alcoholic fatty liver disease (NAFLD). NAFLD is a heterogenous condition ranging from fatty liver to cirrhosis and is itself a growing global problem, with estimated worldwide prevalence of 50% in 2040. Pathophysiology of NAFLD-HCC is not well understood, there are no dedicated screening programs, and there have been no clinical studies of anti-cancer treatments in this population specifically. However, the NAFLD-HCC population appears different than other aetiologies - patients tend to be older, diagnosed at more advanced stages, have more comorbidities, and overall worse prognosis. Understanding of best treatment options for this group of patients is an urgent unmet clinical need. This narrative review discusses NAFLD-HCC pathophysiology and systemic treatment, and offers suggestions for future directions in this therapy area.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1394-1403"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of immunotherapy in gastric cancer with liver metastasis.","authors":"Bogdan Gafton, Stefan Morarasu, Gabriel Dimofte","doi":"10.5306/wjco.v15.i11.1383","DOIUrl":"https://doi.org/10.5306/wjco.v15.i11.1383","url":null,"abstract":"<p><p>Gastric cancer continues to be a significant issue for public health, marked by its widespread occurrence and high mortality rates, even as the incidence of the disease shows a declining trend. The liver is the primary site for metastatic spread, with the peritoneum, lungs, and bones also being common targets. With the advent of biologic treatments and the introduction of immunotherapy for patients with metastatic conditions, the options to treat metastatic gastric cancer have expanded. This diversified therapeutic approach is designed to enhance patient quality of life and prolong survival, showcasing the progress in treatment modalities for individuals with gastric cancer and liver metastases.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1383-1389"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary pancreatic lymphoma: A case report and review of literature.","authors":"Marko M Stojanovic, Vesna Brzacki, Goran Marjanovic, Milica Nestorovic, Jelena Zivadinovic, Miljan Krstic, Marko Gmijovic, Ilija Golubovic, Svetlana Jovanovic, Miroslav P Stojanovic, Katarina Terzic","doi":"10.5306/wjco.v15.i11.1444","DOIUrl":"https://doi.org/10.5306/wjco.v15.i11.1444","url":null,"abstract":"<p><strong>Background: </strong>Primary pancreatic lymphoma (PPL) is a rare tumor that mimics pancreatic adenocarcinoma, leading to diagnostic and therapeutic challenges. PPL accounts for 0.2% of all pancreatic tumors and is typically treated with chemotherapy. However, the long-term survival rates for PPL with chemotherapy and radiotherapy alone are unsatisfactory. Due to the improvements in pancreatic surgery, there is a need to reevaluate the treatment strategies for PPL.</p><p><strong>Case summary: </strong>A 62-year-old male presented to our clinic. A biopsy was unsuccessful, and the imaging was suggestive of pancreatic adenocarcinoma. Therefore, subtotal splenopancreatectomy was performed and histopathology was performed. He was then diagnosed with primary pancreatic diffuse large B-cell lymphoma. He received adjuvant chemotherapy and radiotherapy. Currently, the patient is alive with no evidence of disease 36 months after surgery.</p><p><strong>Conclusion: </strong>The potential role of surgery in the treatment of PPL should be emphasized and added in the management protocol of early stage lymphoma.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1444-1453"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent efficacy and long-term survival of <i>Astragalus</i> polysaccharide combined with gemcitabine and S-1 in pancreatic cancer.","authors":"Guang-Yu Li, Jing Jiang","doi":"10.5306/wjco.v15.i11.1404","DOIUrl":"https://doi.org/10.5306/wjco.v15.i11.1404","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is a highly malignant tumor with a rapid progression rate and a high susceptibility to infiltration and metastasis. <i>Astragalus</i> polysaccharide (APS), a pure Chinese medicine preparation primarily made from the traditional Chinese herb <i>Astragalus</i>, plays a positive role in the treatment of many malignant tumors.</p><p><strong>Aim: </strong>To explore the recent efficacy of APS combined with gemcitabine plus tegafur gimeracil oteracil potassium capsule (S-1) (GS) regimen in the treatment of pancreatic cancer and assess its effect on the immune function and long-term survival of patients.</p><p><strong>Methods: </strong>A total of 97 patients who were diagnosed with pancreatic cancer and received GS chemotherapy at The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine) from March 2021 to December 2021 were included in the retrospective analysis. Among them, 41 patients received APS combined with GS chemotherapy, and 56 patients received GS chemotherapy only. The recent efficacy, immune function, adverse reactions, and long-term survival were compared among these patients.</p><p><strong>Results: </strong>After 4 cycles of treatment, the objective response rate of patients receiving the combined therapy of APS and GS was 51.22%, and the disease control rate (DCR) was 56.10%, higher than those of patients receiving the monotherapy with GS alone (30.36% and 35.71%, respectively). Besides, the percentages of CD3+ T cells (50.18% ± 9.57%) and CD4+ T cells (31.52% ± 5.33%) in the peripheral blood of patients receiving the combined therapy of APS and GS were higher compared with those treated with GS regimen alone [(44.06% ± 8.55%) and (26.01% ± 7.83%), respectively]. Additionally, the incidences of leukopenia, thrombocytopenia, and fatigue in patients receiving the combined therapy of APS and GS were significantly lower than those in patients receiving the monotherapy of GS alone (17.07%, 9.76%, 31.71% <i>vs</i> 37.50%, 28.57%, 60.71%). Moreover, the median survival time of patients receiving the combined therapy of APS and GS was 394 days, significantly longer than that of patients receiving the monotherapy of GS alone (339 days) (hazard ratio: 0.66; 95%CI: 0.45-0.99; <i>P</i> = 0.036). All these differences were statistically significant (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The combined therapy of APS and GS improved the recent efficacy and long-term survival of patients with pancreatic cancer and alleviated chemotherapy-induced immune suppression and adverse reactions.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1404-1411"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation and analysis of the status of cancer health popularization in China, 2023.","authors":"Hai-Tao Hu, Yu-Juan Jiang, Xin-Xin Shao, Yi-Ming Lu, Yan-Tao Tian, Quan Xu","doi":"10.5306/wjco.v15.i10.1269","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1269","url":null,"abstract":"<p><strong>Background: </strong>Cancer presents a significant public health challenge in China, necessitating broad collaboration across society. The Chinese government has articulated a goal to increase the overall five-year survival rate for cancer by 15% by 2030. Achieving this objective requires not only advances in medical technology, but also an improvement in the dissemination of knowledge pertaining to cancer prevention and treatment.</p><p><strong>Aim: </strong>To provide a comprehensive understanding of the status of cancer prevention and level of popularization in China in 2023.</p><p><strong>Methods: </strong>From January 2023 to May 2023, online questionnaires were distributed to 3000 participants, including medical personnel, patients with cancer, their families, and the general public. There were 2711 valid responses, covering the entire nation.</p><p><strong>Results: </strong>A total of 1020 medical personnel and 1691 patients with cancer, their family members, and the general public participated in the survey. Among medical personnel, 93.2% had popularized cancer health. Commonly addressed topics included cancer prevention (85.9%) and cancer screening (77.8%). Primary challenges included time constraints (73.9%), insufficient personnel and material support (66.7%), and uncertainty as to where to begin (49.3%). Among patients with cancer, their family members, and the general public, 93.4% reported reading or watching cancer science popularization materials and 56.9% expressed a desire for deeper understanding. The most sought-after topics in cancer science popularization included cancer screening (80.2%) and cancer prevention (75.8%). The greatest challenge encountered in accessing cancer health popularization was an abundance of misinformation (67.5%).</p><p><strong>Conclusion: </strong>Most clinical doctors, patients, family, and the general public wish to participate in cancer education. However, improvement in the quality of content in cancer prevention and treatment education is required.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1269-1279"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}